Literature DB >> 30410041

A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD).

Raymond K Cross1, Patricia Langenberg2, Miguel Regueiro3, David A Schwartz4, J Kathleen Tracy2, Joseph F Collins2,5, Jonathan Katz6, Leyla Ghazi1, Seema A Patil1, Sandra M Quezada1, Dawn Beaulieu4, Sara N Horst4, Katharine Russman1, Mahrukh Riaz1, Guruprasad Jambaulikar1, Barathi Sivasailam1, Charlene C Quinn2.   

Abstract

INTRODUCTION: Telemedicine has shown promise in inflammatory bowel disease (IBD). The objective of this study was to compare disease activity and quality of life (QoL) in a 1-year randomized trial of IBD patients receiving telemedicine vs. standard care.
METHODS: Patients with worsening symptoms in the prior 2 years were eligible for randomization to telemedicine (monitoring via texts EOW or weekly) or standard care. The primary outcomes were the differences in change in disease activity and QoL between the groups; change in healthcare utilization among groups was a secondary aim.
RESULTS: 348 participants were enrolled (117 control group, 115 TELE-IBD EOW, and 116 TELE-IBD weekly). 259 (74.4%) completed the study. Age was 38.9 ± 12.3 years, 56.6% were women, 91.9% were Caucasian, 67.9% had Crohn's disease (CD) and 42.5% had active disease at baseline. In CD, all groups experienced a decrease in disease activity (control -5.2 ± 5.0 to 3.7 ± 3.6, TELE-IBD EOW 4.7 ± 4.1 to 4.2 ± 3.9, and TELE-IBD weekly 4.2 ± 4.2 to 3.2 ± 3.4, p < 0.0001 for each of the groups) In UC, only controls had a significant decrease in disease activity (control 2.9 ± 3.1 to 1.4 ± 1.4, p = 0.01, TELE-IBD EOW 2.7 ± 3.1 to 1.7 ± 1.9, p = 0.35, and TELE-IBD Weekly 2.5 ± 2.5 to 2.0 ± 1.8, p = 0.31). QoL increased in all groups; the increase was significant only in TELE-IBD EOW (control 168.1 ± 34.0 to 179.3 ± 28.2, p = 0.06, TELE-IBD EOW 172.3 ± 33.1 to 181.5 ± 28.2, p = 0.03, and TELE-IBD Weekly 172.3 ± 34.5 to 179.2 ± 32.8, p = 0.10). Unadjusted and adjusted changes in disease activity and QoL were not significantly different among groups. Healthcare utilization increased in all groups. TELE-IBD weekly were less likely to have IBD-related hospitalizations and more likely to have non-invasive diagnostic tests and electronic encounters compared to controls; both TELE-IBD groups had decreased non-IBD related hospitalizations and increased telephone calls compared to controls. DISCUSSION: Disease activity and QoL, although improved in all participants, were not improved further through use of the TELE-IBD system. TELE-IBD participants experienced a decrease in hospitalizations with an associated increase in non-invasive diagnostic tests, telephone calls and electronic encounters. Research is needed to determine if TELE-IBD can be improved through patient engagement and whether it can decrease healthcare utilization by replacing standard care.

Entities:  

Year:  2019        PMID: 30410041     DOI: 10.1038/s41395-018-0272-8

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  37 in total

1.  React, reset and restore: Adaptation of a large inflammatory bowel disease service during COVID-19 pandemic.

Authors:  Haidee A Gonzalez; Sally Myers; Emma Whitehead; Alisson Pattinson; Katie Stamp; Jack Turnbull; Rebecca Fory; Bethia Featherstone; Amy Wilkinson; Jessica Lisle; Greg Haire; Eileen Henderson; Shaji Sebastia
Journal:  Clin Med (Lond)       Date:  2020-07-27       Impact factor: 2.659

Review 2.  The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care.

Authors:  Jonathan A Beard; Diana L Franco; Benjamin H Click
Journal:  Curr Gastroenterol Rep       Date:  2020-01-30

3.  Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases.

Authors:  Nghia H Nguyen; Jejo Koola; Parambir S Dulai; Larry J Prokop; William J Sandborn; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-27       Impact factor: 11.382

Review 4.  Artificial Intelligence for Disease Assessment in Inflammatory Bowel Disease: How Will it Change Our Practice?

Authors:  Ryan W Stidham; Kento Takenaka
Journal:  Gastroenterology       Date:  2022-01-04       Impact factor: 22.682

5.  Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review.

Authors:  Nghia H Nguyen; Ivonne Martinez; Ashish Atreja; Amy M Sitapati; William J Sandborn; Lucila Ohno-Machado; Siddharth Singh
Journal:  Am J Gastroenterol       Date:  2022-01-01       Impact factor: 10.864

Review 6.  Remote Monitoring and Telemedicine in IBD: Are We There Yet?

Authors:  Lauren A George; Raymond K Cross
Journal:  Curr Gastroenterol Rep       Date:  2020-02-10

7.  Physician Perspectives about Telemedicine: Considering the Usability of Telemedicine in Response to Coronavirus Disease 2019.

Authors:  Jennifer A Lee; Gennaro Di Tosto; Fiona A McAlearney; Steven Miller; Ethan Mezoff; Rajitha D Venkatesh; Jeannie Huang; Jenifer R Lightdale; Jaclyn Volney; Ann Scheck McAlearney
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-07-01       Impact factor: 3.288

Review 8.  Telemedicine and Integrated Multidisciplinary Care for Pediatric IBD Patients: A Review.

Authors:  Lauren M Potthoff
Journal:  Children (Basel)       Date:  2021-04-28

9.  Applying Telemedicine to Multidisciplinary Pediatric Inflammatory Bowel Disease Care.

Authors:  Hilary K Michel; Ross M Maltz; Brendan Boyle; Amy Donegan; Jennifer L Dotson
Journal:  Children (Basel)       Date:  2021-04-21

10.  Crohn's disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic.

Authors:  Sergio Pinto; Erica Loddo; Salvatore Paba; Agnese Favale; Fabio Chicco; Sara Onali; Paolo Usai; Massimo Claudio Fantini
Journal:  J Patient Rep Outcomes       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.